Background & objectives: Patients with locally advanced rectal cancer are treated with neo-adjuvant chemo-radiotherapy to improve resectability and decrease the probability of recurrence. This study aims to assess whether H3K27me3 immunostaining in pre-treatment biopsies of rectal adenocarcinoma may predict response to neo-adjuvant CRT. Methods: We assessed H3K27me3 immunostaining in 43 pretreatment endoscopic biopsies of locally advanced rectal carcinomas treated with neo-adjuvant CRT and correlated it with Tumour Regression Grade (TRG) measured using Dworak system in the following surgical specimen. H3K27me3 immunostain was classified: i) retained (≥ 5% stained neoplastic cells); ii) lost (> 95% stained neoplastic cells); iii) inconclusive (unstained normal and neoplastic cells). Results: H3K27me3 immunostaining was lost in 18 cases, retained in 17 and inconclusive in 8. All tumours with retained H3K27me3 expression had complete tumour regression (TRG 4/5). H3K27me3 loss was significantly associated with absent/ partial tumour regression (TRG 0/1/2) in surgical specimen (P=0.0015) Conclusion: Due to the lower probability to respond to neo-adjuvant CRT, a "watch and wait" approach to avoid side effect of surgery should be used with caution in patients with rectal carcinomas with H3K27me3 loss in the endoscopic pre-treatment biopsy.

H3K27me3 immunohistochemical loss predicts response to neo-adjuvant chemo-radiotherapy (CRT) in patients with locally advanced rectal adenocarcinoma

Caldonazzi, N.;Rizzo, P. C.;Ammendola, S.;Turri, G.;Scarpa, A.;Barresi, V.
2022-01-01

Abstract

Background & objectives: Patients with locally advanced rectal cancer are treated with neo-adjuvant chemo-radiotherapy to improve resectability and decrease the probability of recurrence. This study aims to assess whether H3K27me3 immunostaining in pre-treatment biopsies of rectal adenocarcinoma may predict response to neo-adjuvant CRT. Methods: We assessed H3K27me3 immunostaining in 43 pretreatment endoscopic biopsies of locally advanced rectal carcinomas treated with neo-adjuvant CRT and correlated it with Tumour Regression Grade (TRG) measured using Dworak system in the following surgical specimen. H3K27me3 immunostain was classified: i) retained (≥ 5% stained neoplastic cells); ii) lost (> 95% stained neoplastic cells); iii) inconclusive (unstained normal and neoplastic cells). Results: H3K27me3 immunostaining was lost in 18 cases, retained in 17 and inconclusive in 8. All tumours with retained H3K27me3 expression had complete tumour regression (TRG 4/5). H3K27me3 loss was significantly associated with absent/ partial tumour regression (TRG 0/1/2) in surgical specimen (P=0.0015) Conclusion: Due to the lower probability to respond to neo-adjuvant CRT, a "watch and wait" approach to avoid side effect of surgery should be used with caution in patients with rectal carcinomas with H3K27me3 loss in the endoscopic pre-treatment biopsy.
2022
rectal adenocarcinoma, immunohistochemistry, neoadjuvant therapy
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1082267
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact